Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to $45.8 million.

  • Lineage Cell Therapeutics' Cash & Equivalents rose 45.81% to $40.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 45.81%. This contributed to the annual value of $45.8 million for FY2024, which is 29.19% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Cash & Equivalents stood at $45.8 million for FY2024, which was up 29.19% from $35.4 million recorded in FY2023.
  • Lineage Cell Therapeutics' Cash & Equivalents' 5-year high stood at $55.7 million during FY2021, with a 5-year trough of $32.6 million in FY2020.
  • In the last 3 years, Lineage Cell Therapeutics' Cash & Equivalents had a median value of $45.8 million in 2024 and averaged $44.0 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Cash & Equivalents surged by 243.11% in 2020, and later fell by 29.99% in 2023.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Cash & Equivalents stood at $32.6 million in 2020, then spiked by 71.07% to $55.7 million in 2021, then dropped by 9.19% to $50.6 million in 2022, then declined by 29.99% to $35.4 million in 2023, then climbed by 29.19% to $45.8 million in 2024.